Part I Digitalis glycosides: Mechanisms and manifestations of toxicity

Progress in Cardiovascular Diseases

Volumn 26, Issue 5, 1984, Pages 413-458

  Smith, Thomas W ^a,b   Antman, Elliott M ^a,b   Friedman, Peter L ^a,b   Blatt, Charles M ^a,b   Marsh, James D ^a,b  

^a Brigham and Women's Hospital   (United Kingdom)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; APRINDINE; ATENOLOL; ATROPINE; CANRENOIC ACID; CHARCOAL; DIGITALIS GLYCOSIDE; DIGITOXIN; DIGOXIN; DIGOXIN ANTIBODY; HEMODIALYSIS FLUID; ISOPRENALINE; LIDOCAINE; METOPROLOL; MEXILETINE; NADOLOL; OUABAIN; PHENYTOIN; POTASSIUM; PROCAINAMIDE; PROPRANOLOL; QUINIDINE; TIMOLOL; TOCAINIDE; VERAPAMIL; ACETYLDIGITOXIN; ACETYLDIGOXIN; ACETYLSTROPHANTHIDIN; ANESTHETIC AGENT; ANTACID AGENT; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIDIABETIC AGENT; ANTIINFLAMMATORY AGENT; BARBITURIC ACID DERIVATIVE; CARDIOVASCULAR AGENT; DESLANOSIDE; DESLANOSIDE A; DIURETIC AGENT; GITALIN; LANATOSIDE A; LANATOSIDE B; LANATOSIDE C; UNCLASSIFIED DRUG;

ADVERSE DRUG REACTION; BLOOD AND HEMOPOIETIC SYSTEM; DIGESTIVE SYSTEM; DIGITALIS INTOXICATION; DRUG BLOOD LEVEL; DRUG OVERDOSE; GASTROINTESTINAL SYMPTOM; HEART; HEART ARRHYTHMIA; HUMAN; HYPOKALEMIA; INTOXICATION; NERVOUS SYSTEM; NEUROTOXICITY; ATRIOVENTRICULAR BLOCK; BIOAVAILABILITY; CARDIOTOXICITY; CARDIOVASCULAR SYSTEM; CONGESTIVE CARDIOMYOPATHY; DRUG ACCUMULATION; DRUG DOSE; DRUG ELIMINATION; DRUG INTERACTION; DRUG PROTEIN BINDING; EPIDEMIOLOGY; GASTROINTESTINAL TOXICITY; HEART INFARCTION; PHARMACOKINETICS; REVIEW; TOXICITY;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ANTIBODIES; ARRHYTHMIA; CHOLESTYRAMINE; DIGITALIS GLYCOSIDES; DRUG HYPERSENSITIVITY; ELECTRIC COUNTERSHOCK; ELECTROCARDIOGRAPHY; ENDOCRINE SYSTEM DISEASES; FEMALE; GASTROINTESTINAL DISEASES; HEART CONDUCTION SYSTEM; HEMOPERFUSION; HUMANS; HYPOKALEMIA; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN G; LIDOCAINE; MALE; NA(+)-K(+)-EXCHANGING ATPASE; NERVOUS SYSTEM DISEASES; PHENYTOIN; POTASSIUM; PROCAINAMIDE; QUINIDINE; RENAL DIALYSIS; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; VERAPAMIL; VISION DISORDERS;

EID: 84879282729     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1016/0033-0620(84)90012-4     Document Type: Article

References (672)

1. Digitalis-induced arrhythmias and their management
2. The use of digitalis in acute myocardial infarction
3. New developments in the understanding of the digitalis glycosides
4. Metabolism of digitalis
5. Recognition and therapy of digitalis toxicity
6. Digitalis in non-failing cardiac diseases
7. Assays of digitalis in blood
8. Digitalis arrhythmias: Role of oscillatory afterpotentials
9. Clinical pharmacokinetics of digitalis glycosides
10. An account of the foxglove and some of its medical uses, with practical remarks on dropsy, and other diseases
11. Chronic diseases of the heart
12. Digitalis effects in chronic cardiac cases with regular rhythm in contrast to auricular fibrillation
13. Digitalis
14. Blind study on the action of digitoxin on elderly women
15. Maintenance digoxin in elderly patients
16. Maintenance digoxin after an episode of heart failure: Placebo controlled trial in outpatients
17. Discontinuation of maintenance digoxin therapy in general practice
18. Is maintenance digoxin necessary in patients with sinus rhythm?
19. The efficacy of digitalis withdrawal in an institutional aged population
20. The effects of discontinuing maintenance digoxin therapy: A study of elderly cardiac patients in sinus rhythm
21. The clinical value of digoxin in patients with heart failure and sinus rhythm
22. Long-term digitalis therapy improves left ventricular function in heart failure
23. Digitalis vs placebo in outpatients with heart failure
24. Digitalis and allied cardiac glycosides
25. Digitalis and allied cardiac glycosides
26. Ouabain pharmacokinetics in dog and man: Determination by radioimmunoassay
27. Renal and gastrointestinal excretion of ouabain in dog and man
28. Plasma concentration and urinary excretion kinetics of acetyl strophanthidin
29. Oleander interference in the digoxin radioimmunoassay in a fatal ingestion
30. Pharmacokinetics of Strophanthus glycosides
31. Pharmacokinetics of sqill glycosides
32. The management of heart failure
33. Pain and CPK elevation after intramuscular digoxin
34. Another disadvantage of intramuscular digoxin
35. Determinants of digitalis dosage
36. Drug therapy: Digitalis glycosides
37. Drug therapy: Digitalis glycosides
38. Metabolic factors determining digitalis dosage in man
39. Tritiated digoxin. XIX. Turnover studies in diabetes insipidus
40. Renal tubular secretion of digoxin
41. Acute vasodilator therapy increases renal clearance of digoxin in patients with congestive heart failure
42. Identification by gas chromatography-mass spectroscopy of dihydrodigoxin—A metabolite of digoxin in man
43. Unusually large digitalis requirements: A study of altered digoxin metabolism
44. Digoxin metabolism in patients
45. Administration of tritiated digoxin with and without a loading dose: A metabolic study
46. Digoxin metabolism in obesity
47. Digoxin disposition in obesity Clinical pharmacokinetic investigation
48. A nomogram for digoxin therapy
49. Re-examination of digoxin.dosage regimen: Comparison of the proposed nomograms on formulae in elderly patients
50. Pharmacokinetics of digoxin and derivatives
51. 3H in the rat
52. Absorption rates of some cardiac glycosides and portal blood flow
53. The clinical pharmacokinetics of digoxin
54. Tritiated digoxin. XV. Serum protein binding in human subjects
55. Binding of digitoxin and some related cardeolides to human plasma proteins
56. Studies on digitalis. V. The influence of impaired renal function, hemodialysis, and drug interaction on serum protein binding of digitoxin and digoxin
57. The distribution and concentration of tritiated digoxin in human tissues
58. Tissue concentration and turnover of tritiated digoxin in dogs
59. Correlation of serum concentration with heart concentrations of digoxin in human subjects
60. Human serum and myocardium digoxin
61. The effect of increased serum potassium on the digoxin content of the canine heart
62. Effect of a pharmacologic dose of digoxin on inotropy in hyper- and normokalemic dogs
63. Inhibition of binding of tritiated digoxin to myocardium by sodium depletion in dogs
64. Effect of hemodynamic status on myocardial digoxin binding in hypomagnesemia
65. The role of magnesium in digitalis toxicity
66. Serum and erythrocytic magnesium levels in congestive heart failure: Effect of hydrochlorothiazide
67. Digitalis toxicity and hypomagnesemia
68. Magnesium sulfate in digitalis toxicity
69. The quinidine-digoxin interaction
70. 3H-digoxin in infants
71. Tritiated digoxin. XVIII. Studies in infants and children
72. Serum digoxin concentrations in the human fetus, neonate and infant
73. Plasma digoxin levels in infants
74. Serum levels of digoxin in infants and children
75. Serum digoxin in adults and children
76. Inactivation of digoxin by the gut flora: Reversal by antibiotic therapy
77. Clinical studies on digitoxin (Digitaline Nativelle): With further observations on its use in the single average full dose method of digitalization
78. Clinical pharmacology of digoxin
79. Interactions between digitoxin and other drugs in vitro and in vivo
80. Interactions between digitoxin and other drugs in man
81. Clinical pharmacology and therapeutic use of digitalis glycosides
82. Clinical pharmacokinetics of digitoxin
83. Some aspects of the distribution and disposition of digitoxin
84. The pharmacokinetics and metabolism of digitoxin in man
85. Studies on digitalis. III. Biliary excretion and enterohepatic circulation of digitoxin and its cardioactive metabolites
86. Interruption of the enterohepatic circulation of digitoxin by cholestyramine. II. Effect on metabolic disposition of tritium-labeled digitoxin and cardiac systolic time intervals in man
87. 3H-lanatoside C in man
88. Assay of digitalis glycosides in man
89. Sensitivity to digitalis drugs in acute myocardial infarction
90. Effect of a digitalis drug on ventricular premature beats
91. Klein MD, Lown B, Barr I, et al: Comparison of serum digoxin level measurement with acetyl strophanthidin tolerance testing. Circulation 49:1053–1062
92. Acetyldigitoxin in clinical practice
93. Bioavailability of drugs: The digoxin dilemma
94. Bioavailability of drugs
95. Bioavailability of drugs
96. Dissimilarities of digoxin
97. Absorption of digoxin in patients with malabsorption syndromes
98. Plasma concentrations of digoxin after oral administration in the fasting and post-prandial state
99. Altered absorption of digoxin in patients given propantheline and metoclopramide
100. 3H-digitalis glycosides in experimental animals and man
101. Digitalis intoxication: Treatment with a new steroid-binding resin
102. Malabsorption of digoxin in malabsorption syndromes
103. Impairment of digoxin absorption by neomycin
104. Digoxin—the regulatory viewpoint
105. Bioavailability of digoxin: What the clinician needs to know
106. Absorption of orally given digoxin preparations
107. Comparative study of the absorption, plasma levels, and urinary excretion of the “new” and the “old” Lanoxin
108. Drug interactions with digoxin
109. Drug interactions involving digitalis glycosides
110. Effects of cytostatic drugs on plasma level and renal excretion of β-acetyldigoxin
111. The influence of digoxin particle size on absorption of digoxin and the effect of propantheline and metoclopramide
112. Effect of sulphasalazine on digoxin bioavailability
113. Effect of cholestyramine on digoxin absorption and excretion in man
114. Decreased bioavailability of digoxin due to hypocholesterolemic interventions
115. Cholestyramine enhances digitalis excretion and protects against lethal intoxication
116. Absorption of different commercial preparations of digoxin in the normal human subject, and the influence of antacid, antidiarrhoeal and ion-exchange resins
117. Mechanism of diphenylhydantoin (DPH) induced decrease in serum digoxin (DG) levels
118. Treatment of digoxin intoxication
119. Inhibition of digoxin absorption by neomycin
120. Digitalis toxicity: Drug interactions promoting toxicity and the management of toxicity
121. Influence of gastric pH on digoxin biotransformation. I. Intragastric hydrolysis
122. The development and application of a radioimmunoassay for dihydrodigoxin, a digoxin metabolite
123. Effect of phenobarbital on digitoxin metabolism
124. The effects of antituberculosis drugs on the pharmacokinetics of digitoxin
125. Influence of spironolactone pretreatment on pharmacokinetics and metabolism of digitoxin in rats
126. Metabolism of digitoxin in man and its modification of spironolactone
127. Excretion of radioactive digitoxin by the dog
128. Double isotope dilution derivative assay of digitoxin in plasma, urine and stool of patients maintained on the drug
129. Radioimmunoassay of digitoxin
130. Digitoxin kinetics in patients with impaired renal function
131. Of toads and flowers
132. Spironolactone-induced changes in digoxin kinetics
133. The uptake and binding of six radiolabeled cardiac glycosides by guineapig hearts and by isolated sarcoplasmic reticulum
134. +)-dependent ATPase from cardiac muscle
135. Direct evidence for the intimate relationship between the uptake of digitoxin and activity of the guinea pig heart
136. Alteration of the body distribution of tritiated digoxin by acute hyperkalemia in the dog
137. Influence of potassium depletion on myocardial concentration of tritiated digoxin
138. 3H content in experimental hypokalemic cardiomyopathy
139. 3H-ouabain binding sites and the active NaK transport in skeletal muscle
140. Interaction between digoxin and quinidine
141. Effect of quinidine on plasma concentrations of digoxin
142. Ansteig der Digoxinkonzentration im Serum unter Chinidinmedikation
143. A digoxin/quinidine adverse drug interaction
144. Enhanced cardiac effect of digoxin during quinidine treatment
145. Quinidine-digoxin interaction. Time course and pharmacokinetics
146. Digoxinquinidine interaction. Pharmacolinetic evaluation
147. Digoxin bioavailability during quinidine administration
148. Effect of quinidine on digoxin concentration is skeletal muscle and serum in patients with atrial fibrillation
149. Quinidine-digoxin interaction Evidence for involvement of an extrarenal mechanism
150. Lack of interaction between digoxin and quinidine in cultured heart cells
151. Effect of quinidine on digoxin-inhibited monovalent cation active transport (abstract)
152. Digoxin-quinidine interaction. Changes in canine tissue concentration from steady state with quinidine
153. Clinically significant interaction between digoxin and quinidine
154. Reduction of digoxin-induced inotropism during quinidine administration
155. The effect of quinidine and and other oral antiarrhythmic drugs on serum digoxin. A prospective study
156. Digoxin-quinidine interaction
157. Digoxin-verapamil interaction
158. The influence of verapamil on serum digoxin concentration
159. Acute and chronic pharmacodynamic interaction of verapamil and digoxin in atrial fibrillation
160. Interaction between digoxin and calcium antagonist
161. Digoxin plasma concentrations and nifedipine
162. Amiodarone increases plasma digoxin concentrations
163. Amiodarone-digoxin interaction during treatment of resistant cardiac arrhythmias
164. Digitoxin-quinidine interaction: Pharmacokinetic evaluation
165. Digitoxin elimination reduced during quinidine therapy
166. Interaktion von Chinidin und Digitoxin beim Menschen
167. Is there an interaction between digitoxin and quinidine?
168. Chinidin Interaktion mit Digitoxin
169. Noninteraction of digitoxin and quinidine
170. Studies on digitalis. III. The influence of triiodothyronine on digitalis requirements
171. Serum digoxin in patients with thyroid disease
172. Digoxin metabolism in hypo- and hyperthyroidism. Studies with tritiated digoxin in thyroid disease
173. 3H-digitoxin in patients suffering from hyperthyroidism or hypothyroidism
174. Thyroid-induced alterations in myocardial sodium and potassium activated adenosine triphosphatase, monovalent cation active transport and cardiac glycoside binding
175. Studies on digitalis-induced arrhythmias in glucose- and insulin-induced hypokalemia
176. Suppression of renal excretion of digoxin in hypokalemic patients
177. Assessment of the synergistic relationship between serum calcium and digitalis
178. Effect of digitalis in patients receiving reserpine
179. Anesthesia and digitalis toxicity: An experimental study
180. Ventricular arrhythmias induced by succinylcholine in digitalized patients
181. Blockade of tissue uptake of the antineoplastic agent, doxorubicin
182. Radioimmunoassay of cardiac glycosides
183. Determination of therapeutic and toxic serum digoxin concentrations by radioimmunoassay
184. +-ATPase
185. Clinical application of serum digitoxin levels—a simplified plasma determination
186. Digoxin intoxication and plasma glycoside levels
187. An improved method of estimating digoxin in human plasma
188. Digoxin concentration in right atrial myocardium, skeletal muscle and serum in man: Influence of atrial rhythm
189. Skeletal muscle digoxin concentration during digitalization and during withdrawal of digoxin treatment
190. Skeletal muscle digoxin concentration and its relation to serum digoxin concentration and cardiac effect in healthy man
191. Extracellular versus intracellular digoxin action on bovine myocardium, using a digoxin antibody and intracellular glycoside application
192. Plasma and myocardial digoxin concentrations in patients on oral therapy
193. Monitoring digoxin therapy
194. Digitalis intoxication: Prospective clinical study with serum level correlations
195. Digoxin serum concentration measurement in patients with suspected digitalis-induced arrhythmias
196. Plasma levels of digoxin in relation to toxicity
197. 3H-ouabain from NaK ATPase
198. The enzymatic assay of plasma digoxin
199. Plasma digoxin concentrations in patients on admission to hospital
200. Plasma digoxin concentrations in patients with atrial fibrillation
201. Digitalis intoxication: Specificity and significance of cardiac and extracardiac symptoms. Part I. Patients with digitalis-induced arrhythmias
202. Plasma digoxin concentrations and digoxin toxicity in hospital patients
203. Fallibility of plasma-digoxin in differentiating toxic from non-toxic patients
204. Bestimmung des Serumdigoxins: Ein Weg zur besseren Therapiekontrolle?
205. Measurement of digoxin in plasma and its use in diagnosis of digoxin intoxication
206. Serum digoxin studies in infants and children
207. Serum digoxin by radioimmunoassay
208. A prospective survey of the incidence of cardiac intoxication with digitalis in patients being admitted to hospital and correlation with serum digoxin levels
209. Association between clinical cardiac status laboratory parameters and digoxin usage
210. Plasma digoxin levels in digitalized and toxic patients
211. Digoxin intoxication in infants and children
212. The measurement of plasma digoxin concentration: A comparison of two methods
213. Lebensbedrohliche Digitalisintoxikationen mit und ohne saluretische Zusatztherapie
214. Aktuelle Plasma-Digoxinkonzentration von Patienten bei Krankenhausaufnahme
215. Relation between plasma and red-cell electrolyte concentrations and digoxin levels in children
216. Infant versus adult plasma digoxin levels
217. Serum digoxin levels in patients undergoing cardiopulmonary bypass
218. Radioimmunoassay for digoxin. Technic and clinical application
219. Clinical evaluation of radioimmunoassay of digoxin
220. Serum glycoside levels by rubidium assay
221. Correlative studies of serum digitalis levels and the arrhythmias of digitalis intoxication
222. Dosage de la digoxine par méthode radioimmunologique
223. Radioimmunoassay of serum digoxin in relation to digoxin intoxication
224. Digoxin intoxication: The relationship of clinical presentation to serum digoxin concentration
225. Clinical studies on digoxin intoxication. I. Serum concentration of digoxin in the elderly and the effect of diuretics
226. Serum digoxin and empiric methods in identification of digitoxicity
227. Salivary electrolytes and serum digoxin in the assessment of digitalis intoxication
228. An assessment of digoxin radioimmunoassay
229. The radioimmunoassay of plasma-digoxin
230. Intoxications digitaliques et déviations de l'activité thérapeutique de la digitaline
231. Dosage radio-immunologique des digitalique (digitoxine et digoxine) dans le sang
232. Digitalis intoxication
233. Serial tests of serum digitoxin levels during digitoxin treatment
234. Clinical use of bio-assay of serum digoxin activity
235. Radioimmunoassay for serum digoxin concentration: Methodology and clinical experience
236. Reduction of digoxin toxicity associated with measurement of serum levels
237. Inefficacy of “therapeutic” serum levels of digoxin in controlling the ventricular rate in atrial fibrillation
238. Value of serum digoxin concentration measurement in the control of digoxin therapy in atrial fibrillation
239. Studies on digitals. XIII. A comparison of the effects of potassium on the inotropic and arrhythmia-producing actions of ouabain
240. Correlation of the electrical and mechanical changes in the dog heart during progressive digitalization
241. Effects of maintenance digoxin therapy on systolic time intervals and serum digoxin concentrations
242. Dose-response relation between therapeutic levels of serum digoxin and systolic time intervals
243. Dose-response relationships and plasma concentrations of digitalis in man
244. On the problem of optimum digitalization in man
245. Classical concentration-response relationship between serum digoxin level and contractility indices
246. Digitalis toxicity: Epidemiology and clinical use of serum concentration measurements
247. Serum digoxin concentrations and subjective manifestations of toxicity
248. The serum digoxin test and digoxin toxicity: A Bayesian approach to decision making
249. Salivary electrolytes in the detection of digitalis toxicity
250. Monitoring digoxin therapy. I. Plasma concentrations and an in vitro assay of tissue response
251. Digitalis: Ions, inotropy and toxicity
252. Intensive hospital monitoring of adverse reaction to drugs
253. Adverse drug reactions during hospitalization
254. Bioavailability of digoxin
255. Large-scale digitoxin
256. Relation between digoxin arrhythmia and ABO blood groups
257. The serum digitalis concentration—does it diagnose digitalis toxicity
258. The epidemiology of digoxin
259. An education program in digitalis therapy
260. An outbreak of digoxin intoxication
261. Do patients take digoxin
262. Plasma digoxin measurement and the assessment of extracardiac symptoms of toxicity
263. The carotid sinus: Clinical value of its stimulation
264. Computerassisted digoxin therapy
265. Digoxin prescribing: An evaluation of clinical judgement
266. Toxicity of digitalis in the aged
267. Digoxin in the elderly and in renal failure Contribution of erythrocyte 86-rubidium uptake tests
268. A role for envivonmental factors in the production of digitalis toxicity
269. The role of the nervous system in the cardiovascular effects of digitalis
270. Digoxin “receptor” in neonates: An explanation of less sensitivity to digoxin than in adults
271. Dosage of digoxin in premature infants
272. Serum concentrations and serum half-life of digoxin in premature and mature newborns
273. The use of digitalis in patients with pulmonary disease
274. Absorption of digoxin in severe right heart failure
275. Effect of digoxin on right ventricular function in severe chronic airflow obstruction
276. Digitalis in cardiac failure
277. Heart failure in outpatients. A randomized trial of digoxin versus placebo
278. Digitalis-associated cardiac mortality after myocardial infarction
279. Is digitalis treatment harmful in the year after acute myocardial infarction
280. The effect of digitalis on survival in high risk patients (CASS)
281. Epidemiology of plasma digoxin concentrations in three patient populations
282. Digoxin-prescribing
283. Digitalis update
284. Digoxin prescribing in general practice, 1967–1977
285. Foxglove (Digitalis purpurea) poisoning in farmed red deer (Cervus elaphus)
286. Foxglove tea poisoning
287. The management of heart failure
288. Activation of skinned cardiac cells. Subcellular effects of cardioactive drugs
289. Calcium transients in aequorin-injected frog cardiac muscle
290. Metabolism of cardiac glycosides
291. +)-activated ATPase
292. Active transport of sodium and potassium ions: Mechanism, function, and regulation
293. Biochemical mechanism of the sodium pump
294. Molecular consideration relevant to the mechanism of active transport
295. The sodium-potassium adenosine triphosphatase Pharmacological physiological and biochemical aspects
296. +-ATPase in the inotropic action of digitalis
297. +-ATPase inhibition from digitalis inotropy
298. + in the dog heart
299. Neural factors in digitalis toxicity: Protective effect of C-1 spinal cord transection
300. Localization of the neurally mediated arrhythmogenic properties of digitalis
301. Inhibition of monovalent cation active transport by subtoxic doses of ouabain in the dog
302. Effects of inotropic and arrhythmogenic digoxin doses and of digoxinspecific antibody on myocardial monovalent cation transport in the dog
303. Differing sensitivities of Purkinje fibers and myocardium to inhibition of monovalent cation transport by digitalis
304. Reversal of inotropic effects of digoxin by specific antibodies and their Fab fragments in the conscious dog
305. +) membrane-ATPase and positive inotropic activity of cardenolides in isolated papillary muscles of the guinea pig
306. The influence of calcium on sodium efflux in squid axons
307. The effect of the internal sodium concentration of calcium fluxes in isolated guinea-pig auricles
308. Interdependence of ion transport and the action of ouabain in heart muscle
309. Action of cardiac glycosides on the excitation-contraction coupling in heart muscle
310. Reconstitution of the sodium pump from protein and phosphatidyl serine: Features of ouabain binding
311. Influence of ouabain and dihydroouabain on the circular dichroism of cardiac plasmalemmal microsomes
312. Relationship between myocardial contractility and the effects of digitalis on ionic exchange
313. A possible molecular mechanism of the action of digitalis
314. Is digitalis inotropy associated with enhanced slow inward calcium current?
315. Ouabain increses the slow inward calcium current in ventricular muscle
316. Enhancement of calcium current during digitalis inotropy in mammalian heart: Positive feedback regulation by intracellular calcium?
317. The effects of sodium pump activity on the slow inward current in sheep cardiac Purkinje fibres
318. Inotropic effects and changes in sodium and calcium contents associated with inhibition of monovalent cation active transport by ouabain in cultured myocardial cells
319. Mechanisms of transmembrane calcium movement in cultured chick embryo ventricular cells
320. Comparison of effects of a low extracellular potassium concentration and cardiac glycosides on contractility, monovalent cation transport and NaCa exchange in cultured ventricular cells
321. Changes in cellular Na K and Ca contents monovalent cation transport rate and contractile state during washout of cardiac glycosides from cultured chick heart cells
322. The effects of external cations and ouabain on the intracellular sodium activity of sheep heart Purkinje fibres
323. The effects of ouabain on the transmembrane potentials and intracellular potassium activity of canine cardiac Purkinje fibers
324. Relation between intracellular Na ion activity and tension of sheep cardiac Purkinje fibers exposed to dihydro-ouabain
325. Does sodium pump inhibition produce the positive inotropic effects of strophanthidin in mammalian cardiac muscle?
326. Mechanism of action of therapeutic levels of cardiac glycosides
327. Stimulation and inhibition of the sodium pump by cardioactive steroids in relation to their binding sites and their inotropic effect on guinea-pig isolated atria
328. + pump
329. An analysis of the actions of low concentrations of ouabain on membrane currents in Purkinje fibers
330. Two mechanisms for the inotropic action of ouabain on sheep cardiac Purkinje fiber contractility
331. Stimulation of monovalent cation active transport by low concentrations of cardiac glycosides: Role of catecholamines
332. + transport in rat skeletal muscle
333. +-ATPase in chemically sympathectomized cat peripheral organs
334. Evidence for participation of catecholamines in cardiac action of ouabain
335. Release of noradrenaline from slices of cat spleen by pretreatment with calcium, strontium and barium
336. Ouabain stimulation of noradrenaline transport in guinea pig heart
337. Cardiac glycoside interaction with solubilized myocardial sodium- and potassium-dependent adenosine triphosphatase
338. Ecological chemistry
339. Van Gogh's vision. Digitalis intoxication?
340. The relationship between sodium pump activity and twitch tension in cardiac Purkinje fibres
341. Increase in intracellular sodium ion activity during stimulation in mammalian cardiac muscle
342. Effects of strophanthidin upon contraction and ion exchange in rabbit ventricular myocardium
343. Electromechanical coupling in heart muscle
344. Calcium and cardiac excitation-contraction coupling
345. An effect of ouabain on the superficially located stores of calcium in cardiac muscle cells
346. Lanthanum in heart cell culture. Effect on calcium exchange correlated with its location
347. Voltage clamp and tracer flux data: Effects of a restricted extracellular space
348. Glycocalyx is not required for slow in ward calcium current in isolated rat heart myocytes
349. Removal of sialic acid from cardiac sarcolemma does not affect contractile function in electrically stimulated guinea pig left atria
350. Sodium-calcium ion exchange in cardiac membrane vesicles
351. Stoichiometry of sodium-calcium exchange in cardiac sarcolemmal vesicles
352. Sodium-calcium exchange in regulation of cardiac contractility
353. 2+ activity
354. Potential and tension changes induced by sodium removal in dog Purkinje fibres: Role of an electrogenic sodium-calcium exchange
355. Mechanisms of bradycardia induced by digitalis substances
356. Influence of baroreceptor reflexes on cardiovascular responses of the dog to acetylstrophanthidin
357. The effect of digitalis on the excitability of autonomic nerves
358. Influence of ouabain on cholinergic responses in the sinoatrial node
359. Inhibition of adrenergic cardiac acceleration by cardiac glycosides
360. Antagonistic effects on the sinus node of acetylstrophanthidin and adrenergic stimulation
361. Neuroexcitatory effects of digitalis and their role in the development of cardiac arrhythmias
362. Study of the therapeutic and toxic effects of ouabain by simultaneous observations on the excised and blood-perfused sinoatrial node and papillary muscle preparations and the in-situ heart of dogs
363. Chronotropic effect of cardiac glycosides in cats, dogs and rabbits
364. The differential effects of ouabain on sinus A-V nodal His bundle and idioventricular rhythms
365. Sur le mecanisme reflexe de la bradycardie provoquée par les digitaliquesv
366. A difference in cardiodecelerator action between digitoxin and digitoxigenin
367. Digitalis in the sick sinus syndrome
368. Effects of digitalis on sinus nodal function in patients with sick sinus syndrome
369. Effects of digoxin on sinus nodal function before and after vagal blockade in patients with sinus nodal dysfunction
370. The electrophysiologic effects of ouabain on sinus node and atrium in man
371. Sinus node function in the denervated human heart. Effect of digitalis
372. The chronotropic effect of digitalis studied by direct perfusion of the sinus node
373. An analysis of arrhythmias induced by ouabain in intact dogs
374. The effects of digitalis on the isolated sinus node of the rabbit heart as studied with microelectrodes
375. Arrhythmias and conduction disturbances due to digitalis
376. Digitalis and the sick sinus syndrome. Clinical and electrophysiologic documentation of a severe toxic effect or sinus node function
377. Effects of digitalis on electrical activity of cardiac membranes
378. Electrophysiology and pharmacology of cardiac arrhythmias. IV. Cardiac antiarrhythmic and toxic effects of digitalis
379. The action of cardiac glycosides on the refractory period of heart tissues
380. The action of cardiac glycosides on the excitability and conduction velocity of the mammalian atrium
381. The effects of ouabain on induction of atrioventricular nodal re-entrant paroxysmal supraventricular tachycardia
382. Effects of digitalis on atrial vulnerability
383. Effect of digoxin on atrioventricular conduction. Studies in patients with and without cardiac autonomic innervation
384. The action of ouabain on the function of the atrioventricular node in rabbits
385. Effect of digitalis on the functional refractory period of the A-V node Studies in awake dogs with and without cardiac denervation
386. Effects of autonomic blockade on the inotropic and electrophysiologic response to digitoxin in the intact dog
387. The anti-adrenergic action of digitalis on the refractory period of the A-V transmission system
388. The effects of acetylstrophanthidin on the response of the A-V junction to adrenergic stimulation studied in dogs
389. The effects of digitalis on atrioventricular conduction in man
390. Effects of digoxin on atrioventricular conduction patterns in man
391. Effects of ouabain, atropine, and ouabain and atropine on A-V nodal conduction in man
392. Response of the transplanted, denervated human heart to cardiovascular drugs
393. Depressant effect of digoxin on atrioventricular conduction in man
394. Effects of digitalis on electrical activity of cardiac fibers
395. Electrophysiological effects of strophanthin in the heart
396. The subcellular basis for the mechanism of action of cardiac glycosides
397. Correlation between effects of ouabain on the canine electrocardiogram and transmembrane potentials of isolated Purkinje fibers
398. The effects of digitalis on refractoriness of the intact canine His-Purkinje system
399. 2+-sensitive microelectrodes
400. Binding sites related to ouabain-induced stimulation or inhibition of the sodium pump
401. Stimulation and inhibition of the sodium pump by cardiotonic steroids in relation to their binding sites and their inotropic effect on guinea-pig isolated atria
402. Serial serum digoxin concentrations and quantitative electrocardiographic changes
403. Correlation between electrocardiographic changes, serum digoxin and total body digoxin content
404. Effects of digitalis on human ventricular refractoriness
405. Toxic effects of ouabain on Purkinje fibers and ventricular muscle fibers
406. Effects of ouabain on canine Purkinje fibers in situ or perfused with blood
407. On the inotropic and arrhythmogenic effects of digitalis
408. Calcium ions and membrane current changes induced by digitalis in cardiac Purkinje fibers
409. Ouabain effects on cardiac contraction action potential and cellular potassium
410. The effect of the cardiac membrane potential on the rapid availability of the sodium carrier system
411. The actions of ouabain on intracellular coupling and conduction velocity in mammalian ventricular muscle
412. Effects of blood perfusion on electrophysiologic properties of canine Purkinje fibers
413. Mechanisms of digitalis toxicity. Effects of ouabain on phase four of canine Purkinje fiber transmembrane potentials
414. Suicidal and accidental digoxin ingestion: Report of fives cases with serum digoxin level correlations
415. A new interpretation of the pacemaker current in calf Purkinje fibers
416. A study of the ionic nature of the pace-maker current in calf Purkinje fibers
417. Effect of ouabain on the current underlying spontaneous diastolic depolarization in cardiac Purkinje fibers
418. The mechanism of oscillatory activity at low membrane potentials in cardiac Purkinje fibers
419. A cellular mechanism for the generation of ventricular arrhythmias by acetylstrophanthidin
420. Effect of changes in cycle length on diastolic depolarization produced by ouabain in canine Purkinje fibers
421. Transient depolarizations induced by acetylstrophanthidin in specialized tissue of dog atrium and ventricle
422. The effect of tension on acetylstrophanthidin-induced transient depolarization and aftercontractions in canine myocardial and Purkinje tissues
423. Effect of transmembrane potential on oscillatory potentials induced by acetylstrophanthidin in canine ventricular tissues
424. Relative inotropic and arrhythmogenic effects of five cardiac steroids in ventricular myocardium: Oscillatory afterpotentials and the role of endogenous catecholamines
425. Action potentials, afterpotentials and arrhythmias
426. Triggered activity in cardiac muscle fibers of the simian mitral valve
427. Cellular mechanism for cardiac arrhythmias
428. Ionic mechanisms of pacemaker activity in cardiac Purkinje fibers
429. Role of sodium in strophanthidin toxicity of Purkinje fibers
430. Effects of tetrodotoxin, lidocaine, verapamil and AHR-2666 on ouabain-induced delayed afterdepolarization in canine Purkinje fibers
431. Effect of calcium on acetylstrophanthidin-induced transient depolarizations in canine Purkinje tissue
432. Transient inward current underlying arrhythmogenic effects of cardiotonic steroids in Purkinje fibers
433. Interrelationship between automaticity and conduction in Purkinje fibers
434. Electrical stimulation to estimate the degree of digitalization
435. Effect of heart rate on electrically induced repetitive ventricular responses in the digitalized dog
436. Effects of cardiac glycosides on spontaneous efferent activity in vagus and sympathetic nerves of cats
437. Effects of ouabain on spontaneous afferent activity in the aortic and carotid sinus nerves of cats
438. Nonuniform cardiac sympathetic nerve discharge. Mechanism for coronary occlusion and digitalis-induced arrhythmia
439. Correlation of ouabain-induced arrhythmia and nonuniformity in the histamine-evoked discharge of cardiac sympathetic nerves
440. Effect of timolol on autonomic neural discharge associated with ouabain induced arrhythmia
441. Role of adrenergic influences in digitalis-induced arrhythmia
442. Cardiac sympathetic nerve activity. Changes induced by ouabain and propranolol
443. Autonomic nervous system actions of cardiac glycosides
444. Effect of digitalis on carotid sinus baroreceptor activity
445. Über die Wirkung von Digitalis and Strophanthin auf die Aktionspotentiale der Chemorezeptoren im Glomus caroticum der Katze
446. Über die Bedeutung der Chemorezeptoren der Carotis und Aorta für die toxische Digitalisbradykarkie bei der Katze
447. Reflex cardiovascular effects of epicardial stimulation by acetylstrophanthidin in dogs
448. Studies of left ventricular receptors, signalling in non-medullated vagal efferents
449. Effects of microinjections of ouabain into certain medullary areas in cats
450. Neuroexcitatory effects of digoxin in the cat
451. Enhancement of phrenic nerve activity by digoxin: An effect dependent upon intact ninth and tenth cranial nerves
452. Zentrale und periphere Beeinflussung der Atmung durch toxische Herzglykosiddosen and der Ratte
453. Effects of microinjection of ouabain into the hypothalamus in cats
454. Changes in spinal neural mechanims associated with digitalis administration
455. Effect of diphenylhydantoin and lidocaine on cardiac arrhythmias induced by hypothalamic stimulation
456. Effect of ouabain and its interaction with diphenylhydantoin on cardiac arrhythmias induced by hypothalamic stimulation
457. Effect of cardiac glycosides on a sympathetic ganglion
458. The action of cardiac glycosides on autonomic ganglia
459. The action of ouabain on the chronotropic effects of sympathetic nerve stimulation and isoproterenol
460. The action of strophanthin upon suprarenal secretion
461. The effect of ouabain on the secretion of catecholamines and on the intracellular concentration of potassium
462. Interactions of digitalis with the autonomic nervous system and their relationship to cardiac arrhythmias
463. The central nervous system as a site of action for the coronary vasoconstriction effect of digoxin
464. Neurogenic effect of digoxin on vascular resistance during hypotension
465. Dependence of the neurogenic vascular resistance effect of digitalis on the background level of sympathetic activity in skeletal muscle
466. The neurogenic vasoconstrictor effect of digitalis on coronary vascular resistance
467. Carotid sinus syncope and its bearing on the mechanism of the unconscious state and convulsions
468. Reappraisal of digitalis. Part IX. Digitalis toxicity
469. Effects of drugs on cardiac standstill induced by pressure on the carotid sinus
470. The effects of the digitalis bodies on the nervous system: An analysis of the mechanism of cardiac slowing, nausea and vomiting, psychosis, and visual disturbances following digitalis therapy
471. Carotid sinus reflex changes produced by digitalis
472. Decrease in cardiac activity by carotid sinus baroreceptor reflex
473. A mechanism of the vagal effect of cardiac glycosides
474. Use of edrophonium (Tensilon) to detect early digitalis toxicity
475. Antagonistic effect of digitalis glycosides to vagus stimulation
476. Release and exchange of neurotransmitters in synaptosomes Effect of the ionophore A 23187 and of ouabain
477. Ouabain stimulation of noradrenaline transport in guinea pig heart
478. 3H] ouabain binding to some sympathetically innervated organs of the cat
479. Effects of a digitalis glycoside on coronary and systemic dynamics in conscious dogs
480. Clinical implications of differences in pharmacodynamic action of polar and nonpolar cardiac glycosides
481. Digoxin and the norepinerphrine response in vascular smooth muscle Mechanism of potentiation
482. Forebrain noradrenergic mechanisms and digitalis-induced ventricular arrhythmias
483. Centrally mediated protective effects of dopamine agonists on digitalis-induced ventricular arrhyhmias
484. Effect of arrhythmogenic doses of deslanoside on the uptake of monoamines in brain tissue and in cardiac tissue
485. +-ATPase during heart block produced by chronic digoxin treatment
486. Accumulation of radioactive cardiac glycosides by various brain regions in relation to the dysrhythmogenic effect
487. Inotropic and toxic effects of a polar cardiac glycoside derivative in the dog
488. Opposing responses in sympathetic nerve activity induced by central injections of ouabain
489. +-adenosine triphosphatase in the cat
490. Digoxin toxicity: Primary sites of drug action on the sympathetic nervous system
491. Cardiac toxicity of ouabain and acetylstrophanthidin: Influence of afferent denervation
492. Depression by reflexes of the pressure and cardiotoxic responses to ouabain
493. Improvement of the toxic: inotropic dose ratio of digoxin by excluding central nervous system influences on the heart
494. Involvement of adrenergic nervous influences in ouabain-induced nonuniformity of ventricular repolarization
495. Role of catecholamines in the central mechanism of emetic response induced by peruvoside and ouabain in cats
496. Effect of deslanoside on brain and spinal cord levels of serotonin and 5-hydroxyindoleacetic acid and tryptophan hydroxylase activity
497. Effects of serotonin and deslanoside on cardiac rhythm in the cat
498. Effects of serotonin antagonists on digitalis-induced ventricular arrhythmias
499. Cardiac histamine-ouabain interaction: Potentiation by ouabain of the arrhythmogenic affects of histamine
500. Histaminergic mechanism involved in the centrally mediated effects of ouabain
501. The influence of metiamide on ouabain cardiotoxicity
502. Influence of reserpine and beta TM-10 on digitalis-induced ventricular arrhythmia
503. Some aspects of the antiarrhythmic activity of reserpine
504. Deleterious effects of bretylium in cats with digitalis-induced ventricular tachycardia
505. Role of the adrenergic nerve terminal in digitalis-induced cardiac toxicity: A study of the effects of pharmacologic and surgical denervation
506. The action of reserpine 6-hydroxydopamine and bretylium on digitalis-induced cardiotoxicity
507. Effect of cardiac beta-adrenergic blockade or denervation on cardiotoxicity of digoxin and an aminosugar cardenolide
508. Suppression by clonidine (St-155) of cardiac arrhythmias induced by digitalis
509. Actions of clonidine and 2-(2-methyl-6-ethyl-cyclohexylamino)-2-oxazoline on postganglionic autonomic nerves
510. Depression of cardiac sympathetic nerve activity by diphenylhydantoin
511. Differential species sensitivity to the inhibitory effect of cardiac glycosides on H-one-noradrenaline acumulation by tissue slices
512. Modification of the cardiotoxic action of digoxin by 6-hydroxydopamine and adrenalectomy
513. The effect of vagus nerve stimulation upon vulnerability of the canine ventricle
514. The importance of a central adrenergic mechanism in the cardiovascular responses to ouabain
515. Neurally mediated augmentation of arrhythmogenic properties of highly polar cardiac glycosides
516. Physiology and pharmacology of vomiting
517. Das Aktionspotenial and Mechanogram des Herzmuskels unter dem Einfluss der Dehnung
518. The role of arterial pressure in the induction of idioventricular rhythms under cyclopropane anesthesia
519. Antagonism of adrenergically-induced cardiac arrhythmias by dichloroisoproterenol
520. Effects of ouabain on the splanchnic circulation
521. Role of neural mechanisms in digoxin induced mesenteric vasoconstriction in dogs
522. Studies on digitalis. X. Effects of ouabain on forearm vascular resistance and venous tone in normal subjects and in patients in heart failure
523. Studies on digitalis. I. Direct effects on peripheral vascular resistance
524. The role of the sodium pump in the control of vascular tone in the rat
525. Neurally mediated and direct effects of acetyl strophanthidin on canine skeletal muscle vascular resistance
526. Localization of the neurally mediated coronary vasoconstrictor properties of digitalis in the cat
527. The effects of acetylstrophanthidin and ouabain on the sympathetic adrenergic neuroeffector junction in canine vascular smooth muscle
528. Prejunctional cholinergic modulation of adrenergic neurotransmission in the cardiovascular system
529. Prejunctional inhibition of norepinephrine release caused by acetylcholine in the human saphenous vein
530. Mechanism of action of digitalis glycosides (II)
531. The spectrum of mesenteric infarction
532. Cardiac and peripheral vascular effects of digitalis in clinical cardiogenic shock
533. Ouabain-induced hypertension in a patient with decompensated hypertensive heart disease
534. Effects of intraarterial ouabain on mesenteric and carotid hemodynamics
535. Effects of ouabain on splanchnic hemodynamics in the rhesus monkey
536. The effect of digoxin in the splanchnic circulation in ventricular failure
537. The vagal control of the jejunal and ileal motility and blood flow
538. The effect of graded vasoconstrictor fiber stimulation on the intestinal resistance and capacitance vessels
539. Effects of vasoactive agents on intestinal blood flow and motility in the dog
540. Mesenterial Infarkt bei Digitalis Intoxication
541. Effects of digoxin on isolated pulmonary vessels
542. Verapamil and nifedipine inhibition of contractions induced by potassium and noradrenaline in human mesenteric arteries and veins
543. The role of carotid body chemoreceptors in the respiratory effects of digoxin
544. Digitalis toxicity during acute hypoxia in intact conscious dogs
545. Cardiac and respiratory effects of digitalis during chronic hypoxia in intact conscious dogs
546. The effect of diphenylthiohydantoin (DPTH) on digitalis induced cardiac arrhythmias
547. Effects of intravenous infusion of ouabain on respiration
548. Untersuchungen über die muskellahmende Wirkung des Strophantus
549. Accidental poisoning of children with digitalis
550. Accidental digitalis intoxication in children
551. EEG and massive digitalis intoxication. A case of epilepsy with respiratory manifestations and prolonged apnea
552. Respiratory effects of digoxin and ouabain in the dog
553. The cytoarchitecture of the brain stem of the cat
554. Digoxin induced intestinal vasoconstriction
555. Digitalis and the mesenteric circulation
556. Effect of digitalis on estimated splanchnic blood flow
557. Shock, intestinal ischemia and digitalis
558. Trigeminal neuralgia from digitalis intoxication
559. Paranoid delusions and auditory hallucinations associated with digoxin intoxication
560. Digitalis delirium in elderly patients
561. Formed visual hallucinations as digitalis toxicity
562. The use of color vision measurement in the diagnosis of digoxin toxicity
563. Color vision deficiencies: A common sign of intoxication in chronically digoxin-treated patients
564. Digoxin-associated thrombocytopenia
565. Digitalis allergy, Digoxin-induced vasculitis
566. Digitalis allergy: A study of 1720 skin tests on 430 patients
567. Gynecomastia during digitalis therapy
568. Subjective assessment of sexual dysfunction of patients on long-term administration of digoxin
569. Cerebrospinal fluid digoxin concentrations in humans
570. The electrocardiogram in digitalis intoxication
571. Asymptomatic digoxin toxicity
572. Digitoxin poinsoning
573. Influence of extracellular potassium concentration on myocardial uptake and inotropic effect of tritiated digoxin
574. Effect of ouabain on potassium exchange in the mammalian heart
575. The effects of the ionic milieu on the response of cardiac muscle to cardiac glycosides
576. Kalium und Digitalistoxizität
577. Potassium and the monophasic action potential, ECG, conduction and arrhythmias
578. The effect on man of potassium administration in relation to digitalis glycosides with special reference to blood serum potassium, the electrocardiogram and ectopic beats
579. The effect of intravenous administration of potassium chloride on ectopic rhythms ectopic beats and disturbances of A-V conduction
580. Paroxysmal atrial tachycardia with block
581. Decrease in serum potassium concentrations and appearance of cardiac arrhythmias during infusion of potassium with glucose in potassium-depleted patients
582. Effect of lidocaine on the electrophysiological properties of ventricular muscle and Purkinje fiber
583. Electrophysiological effects of diphenylhydantoin on canine Purkinje fibers
584. Action of diphenylhydantoin on the electrical properties of isolated rabbit and canine atria
585. Electrophysiological actions of lidocaine on canine ventricular muscle and Purkinje fibers
586. Effects of therapeutic concentrations of diphenylhydantoin on transmembrane potentials of normal and depressed Purkinje fibers
587. The effect of lidocaine on components of excitability in long mammalian cardiac Purkinje fibers
588. Quantitative study of the effect of lidocaine on the threshold for ventricular fibrillation in the dog
589. Interrelationships between external potassium concentration and lidocaine: Effects on canine Purkinje fiber
590. In vivo electrophysiological effects of lidocaine in canine acute myocardial infarction
591. The electrophysiological properties of diphenylhydantoin sodium as compared to procaine amide in the normal and digitalis-intoxicated heart
592. Electrophysiological effects of direct current countershock before and after ouabain sensitization and after diphenylhydantoin in the dog
593. The clinical use of diphenylhydantoin (Dilantin) in the treatment and prevention of cardiac arrhythmias
594. Current status of diphenylhydantoin in heart disease
595. Diphenylhydantion in cardiac arrhythmias
596. Relationship between the plasma level of diphenylhydantoin sodium and its cardiac antiarrhythmic effects
597. The use of beta-adrenergic receptor blocking drugs in dysrhythmias
598. Sensitivity to propranolol after digoxin intoxication
599. Effects of glucagon on atrioventricular conduction and ventricular automaticity in dogs
600. Effect of quinidine and procaine amide upon acetylstrophanthidin cardiotoxicity
601. Protection from digitalis toxicity with the prophylactic use of diphenylhydantoin sodium. An arrhythmic-inotropic dissociation
602. Initiation of sustained rhythmic activity by single propagated action potentials in canine cardiac Purkinje fibers exposed to sodium-free solution or to ouabain
603. Slow conduction and reentry in the ventricular conducting system. II. Single and sustained circus movement in networks of canine and bovine Purkinje fibers
604. Ionic basis of transient inward current induced by strophanthidin in Purkinje fibers
605. Role of calcium ions in transient inward currents and after contractions induced by strophanthidin in cardiac Purkinje fibers
606. Effect of various antiarrhythmic agents on ouabain-induced accelerated escape rhythms (Abstract)
607. The effect of verapamil on latent pacemakers in the canine heart
608. Antiarrhythmic efficacy of aprindine on several types of ventricular arrhythmias
609. Effect of mexiletine, a new anticonvulsant agent, on experimental cardiac arrhythmias
610. The effect of amiodarone, a new antianginal drug, on cardiac muscle
611. Use of potassium canrenoate to suppress ouabain-induced ventricular arrhythmias in dogs
612. Digitalis intoxication following conversion to sinus rhythm
613. Complications and limitations of direct current countershock
614. DC cardioversion causing ventricular fibrillation
615. Cardioversion causing ventricular fibrillation
616. Cardioversion and digitalis drugs: Changed threshold to electric shock in digitalized animals
617. Postcountershock arrhythmias in untreated and digitalized dogs
618. Cardioversion and digitalis. II. Clinical Studies
619. Effects of apparently nontoxec doses of digoxin on ventricular ectopy following direct-current electrical shocks in dogs
620. Safety of electrical cardioversion in patients without digitalis toxicity
621. Cardiac arrhythmias following condenser discharges and their dependence upon strength of current and phase of cardiac cycle
622. Cardiac arrhythmias in chronic cor pulmonale
623. Observations on digitalis intoxication
624. Four cases of massive digitalis poisoning
625. Atrioventricular block due to accidental digoxin ingestion treated with atropine
626. Massive digoxin overdose: Observations on hyperkalaemia and plasma digoxin levels
627. Intoxication digitalique aiguë (70 observations)
628. Treatment of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments: Experience in 26 cases
629. Digoxin serum half-life following suicidal digoxin poisoning
630. Clinical course of intentional digoxin overdosage without specific therapeutic intervention
631. Tritiated digoxin. WIV. Enterohepatic circulation, absorption and excretion studies in human volunteers
632. Absorption of digoxin in patients with malabsorption syndrome
633. Peritoneal dialysis and hemodialysis of tritiated digoxin
634. The effect of cardiopulmonary bypass on plasma digoxin concentrations
635. Constancy of myocardial digoxin concentration during experimental cardiopulmonary bypass
636. Serum digitalis and arrhythmia in patients undergoing cardiopulmonary bypass
637. Effect of exchange transfusions on plasma digoxin levels
638. Hemoperfusion in the management of digoxin toxicity
639. Advanced digoxin toxicity in renal failure: Treatment with charcoal hemoperfusion
640. Digoxin and digitoxin elimination in man by charcoal hemoperfusion
641. Digoxin overdose: Limitations of hemoperfusion-hemodialysis treatment
642. Is hemoperfusion effective in the treatment of digoxin intoxication?
643. Haemoperfusion in the management of digoxin toxicity: It is warrented?
644. Digoxin-specific antibodies
645. Characterization of antibodies of high affinity and specificity for the digitalis glycoside digoxin
646. +-activated adenosine triphosphatase inhibition
647. Kinetics of interactions between antibodies and haptens
648. Determination of antibodyhapten association kinetics: A simplified experimental approach
649. Kinetics of antibody-hapten interaction: Comparison of IgG and Fab
650. Immunological protection against digoxin toxicity
651. Persistence of hapten-antibody complexes in the circulation of immunized animals after a single intravenous injection of hapten
652. Biological activity of digoxin-specific antiera
653. Effects of digoxin-specific antibodies on accumulation and binding of dogoxin by human erythrocytes
654. The electrophysiologic effects of low and high digoxin concentrations of isolated mammalian cardiac tissue: Reversal by digoxin-specific antibody
655. The isolation of digoxin-specific antibody and its use in reversing the effects of digoxin
656. Reversal of ouabain and acetyl strophanthidin effects in normal and failing cardiac muscle by specific antibody
657. Reversal of digoxin toxicity with specific antibodies
658. Effects of sheep digoxin-specific antibodies and their Fab fragments on digoxin pharmacokinetics in dogs
659. Immunogenicity and kinetics of distribution and elimination of sheep digoxin-specific IgG and Fab fragments in the rabbit and baboon
660. Reversal of advanced digitoxin toxicity and modification of pharmacokinetics by specific antibodies and Fab fragments
661. Reversal of advanced digoxin intoxication with Fab fragments of digoxin-specific antibodies
662. Le traitement d'uns intoxication digitalique massive (20 mg de digitoxine) par les anticorps anti-digoxine fractionnes (Fab)
663. Fab fragments of digoxin-specific antibodies used to reverse ventricular fibrillation induced by digoxin ingestion in a child
664. Massive digoxin poisoning treated with Fab fragments of digoxin-specific antibodies
665. Cardiac glycoside-specific antibodies in the treatment of digitalis intoxicatin
666. High-affinity monoclonal antibodies to the cardiac glycoside, digoxin